Metrics as of 10/13/2026, 06:31 PM (Berlin time), refresh in progress.
Definium Therapeutics Stock
Definium Therapeutics, Inc.
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- Robert Barrow
- Employees
- 106
- Market cap
- $4.6 B
- IPO
- 15/11/2016
Definium Therapeutics, Inc. is a clinical-stage biopharmaceutical firm headquartered in New York, USA. The company is dedicated to developing innovative therapeutic solutions for various brain health conditions and neurological disorders. Its pipeline features key experimental drug candidates such as MM120, which is…
Company description based on the data provider's company data, AI-assisted, created on 16/10/2026. Not investment advice.
Definium Therapeutics stock: price history
1D
-1.7%
1W
-2.9%
1M
-11.1%
6M
+57.7%
YTD
+158.3%
1Y
+182.3%
2Y
+539.3%
5Y
+2.9%
10Y
–
Next earnings date
Next earnings date
05/11/2026 (in 19 days)
Volatility around earnings
~67% weaker price swings than usual
Ask the agents about Definium Therapeutics
Analyst assessment of Definium Therapeutics
PRICE TARGET LOW
US$52.00
CONSENSUS
US$67.45
MEDIAN
US$68.00
PRICE TARGET HIGH
US$79.00
0
STRONG BUY
12
BUY
0
HOLD
0
SELL
0
STRONG SELL
12
TOTAL · Buy
As of: 15/09/2026
Definium Therapeutics stock metrics
P/E
-10.05
P/B
4.17
EV/EBITDA
-11.69
RETURN ON EQUITY
-17.3%
NET MARGIN
0.0%
DEBT/EQUITY
0.04
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
97.1%
FLOAT SHARES
128,871,063
AVG. DAILY VOLUME (30D)
2,245,900
Insider transactions (SEC)
Wiley Matthew T.
Karlin Daniel
Barrow Robert
Sullivan Mark
Roberts Brandi
Attention
1 mention today in US forums, about the same as yesterdayPrice since yesterday: -1.7%
Forums (Reddit)
Institutional holders
Dividends & Stock splits
Comparable stocks
Frequently asked questions about Definium Therapeutics stock
What does Definium Therapeutics do?
Definium Therapeutics, Inc. is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is Robert Barrow, the company employs around 106 people.
The IPO was on 15/11/2016; the stock trades on NASDAQ under the ticker DFTX.
What do analysts say about Definium Therapeutics stock?
12 analysts rate the stock, the consensus is Buy (as of 15/09/2026).
The average price target is US$67.45, ranging from US$52.00 to US$79.00, with a median of US$68.00.
This is an external assessment, not a statement by Market Jury.
When does Definium Therapeutics report next?
The next earnings date is 05/11/2026.
Around past earnings, price swings were roughly -67% stronger than usual.
Does Definium Therapeutics pay a dividend?
No, Definium Therapeutics currently does not pay a dividend.
Which stocks are comparable to Definium Therapeutics?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
How can I get Definium Therapeutics stock analyzed?
Clicking "Analyze stock" lets five strategies assess Definium Therapeutics against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.